Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Novartis has performed well in the previous ... Top drugs like Entresto (cardiovascular) and Cosentyx (psoriasis, spondylitis and arthritis) performed well in 2024. Cosentyx sales are being ...

Novartis operates as a single global operating segment. It now concentrates on four core therapeutic areas — cardiovascular, renal, metabolic, immunology, neuroscience and oncology. Top drugs like ...

Comments: Sales growth in the quarter was mainly driven by Entresto with $2.2 billion in sales, up 33%, Kesimpta sales of $950 million, up 48%, Kisqali sales of $902 million, up 48%, Cosentyx sales of ...

The complainant alleged a Novartis employee based in the U.K. liked two LinkedIn posts about the approval of Cosentyx in hidradenitis suppurativa. The posts were by a U.S. academic and a news outlet.

Bristol Myers Squibb and Novartis are leading drugmakers that generate consistent revenue and profits. Both companies are facing patent cliffs, but are innovative enough to navigate past them.

Novartis' top-selling drug is Entresto, a legacy medicine for heart failure whose sales in the third quarter increased by 26% year over year to $1.9 billion. Cosentyx, a drug for plaque psoriasis ...